Recurrent Wilms Tumor and Other Childhood Kidney Tumors Clinical Trial
Official title:
Observational - Characterization of Urinary Metabolite Profiles in Wilms Tumor
This research study is looking at biomarkers in urine samples from patients with Wilms tumor. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment
PRIMARY OBJECTIVES:
I. To characterize the urinary metabolite signature of 10 stage III, favorable-histology,
Wilms tumor patients from the Cooperative Human Tissue Network (CHTN) Databank, as distinct
from 10 normal controls.
II. To characterize and compare the urinary metabolite profile in 50 randomly selected,
stage III, favorable-histology, Wilms tumor patients enriched with an additional 30 stage
III Wilms tumor patients who have relapsed.
III. To establish if the potential poor outcome (defined as relapse) in the
favorable-histology group has a specific metabolite signature.
IV. To characterize the urinary metabolite signature of Wilms tumor in patients with
unfavorable histology (diffuse anaplasia) and compare it to those with favorable histology.
OUTLINE:
Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic
resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also
be examined by NMR and PCA.
;
Observational Model: Case Control, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01118078 -
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
|
N/A | |
| Completed |
NCT01305200 -
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
|
Phase 3 | |
| Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
| Completed |
NCT01502410 -
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT00831844 -
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
| Completed |
NCT01586104 -
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
|
N/A | |
| Completed |
NCT00897637 -
Gene Expression Profiles to Categorize Wilms Tumors
|
N/A | |
| Completed |
NCT00309907 -
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT00331643 -
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT00012181 -
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
|
Phase 1 |